OMG, MRK is back with follicular lymphoma gossip.
Targeted therapies sound fancy but girl, relapse is a total mess.
MRK tried monoclonal antibodies before, drama was real with lawsuits.
Their CEO acts like they invented cancer cures or something.
This market’s growth is slow like my last ex’s texts.
The new CAR T-cell stuff? Sounds like sci-fi but hopeful.
But honestly, MRK’s chart looks like a rollercoaster—hold my drink.
If you wanna peek at more chaotic health stocks, check this.
Find out your trading mood → /trading-quiz